VistaGen Therapeutics (NASDAQ:VTGN) Downgraded to “Sell” Rating by Wall Street Zen

VistaGen Therapeutics (NASDAQ:VTGN) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Other research analysts have also issued research reports about the company. Maxim Group reaffirmed a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, January 21st. William Blair restated a “market perform” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Finally, Stifel Nicolaus lowered shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price on the stock. in a report on Wednesday, December 17th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, VistaGen Therapeutics presently has a consensus rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Price Performance

VistaGen Therapeutics stock opened at $0.61 on Friday. The firm has a market capitalization of $24.13 million, a P/E ratio of -0.32 and a beta of 0.29. VistaGen Therapeutics has a one year low of $0.43 and a one year high of $5.14. The business has a fifty day moving average price of $0.60 and a 200-day moving average price of $2.38.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Thursday, February 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.06. The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.14 million. Sell-side analysts expect that VistaGen Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Trading of VistaGen Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE lifted its holdings in shares of VistaGen Therapeutics by 926.0% during the 3rd quarter. Bank of America Corp DE now owns 34,657 shares of the company’s stock worth $123,000 after acquiring an additional 31,279 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in VistaGen Therapeutics by 123.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 151,874 shares of the company’s stock valued at $101,000 after acquiring an additional 83,857 shares during the last quarter. State Street Corp raised its position in VistaGen Therapeutics by 25.0% during the fourth quarter. State Street Corp now owns 121,114 shares of the company’s stock valued at $80,000 after purchasing an additional 24,256 shares in the last quarter. Marshall Wace LLP bought a new stake in VistaGen Therapeutics during the second quarter worth about $69,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in VistaGen Therapeutics during the fourth quarter worth about $68,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.